Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment
Authors
Keywords
Cancer treatment, Autophagic cell death, Apoptosis, Immunoblotting, Small interfering RNAs, Transcription factors, Cell staining, Gene expression
Journal
PLoS One
Volume 11, Issue 2, Pages e0149388
Publisher
Public Library of Science (PLoS)
Online
2016-02-13
DOI
10.1371/journal.pone.0149388
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NFκB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth
- (2015) Xiaojun Zha et al. CANCER LETTERS
- Spatial Control of the TSC Complex Integrates Insulin and Nutrient Regulation of mTORC1 at the Lysosome
- (2014) Suchithra Menon et al. CELL
- Rapamycin: One Drug, Many Effects
- (2014) Jing Li et al. Cell Metabolism
- A Novel Mechanism by Which Tissue Transglutaminase Activates Signaling Events That Promote Cell Survival
- (2014) Lindsey K. Boroughs et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer
- (2014) Hui Jun Lim et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Simultaneously Targeting Tissue Transglutaminase and Kidney Type Glutaminase Sensitizes Cancer Cells to Acid Toxicity and Offers New Opportunities for Therapeutic Intervention
- (2014) William P. Katt et al. MOLECULAR PHARMACEUTICS
- Systematic identification of signaling pathways with potential to confer anticancer drug resistance
- (2014) C. A. Martz et al. Science Signaling
- Genetic and Pharmacologic Inhibition of mTORC1 Promotes EMT by a TGF- -Independent Mechanism
- (2013) I. Mikaelian et al. CANCER RESEARCH
- PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies
- (2013) Akio Iwanami et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer
- (2012) Adrian Britschgi et al. CANCER CELL
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor κ Light Chain Enhancer of Activated B Cells (NFκB) Signaling Controls Basal and DNA Damage-induced Transglutaminase 2 Expression
- (2012) Lingbao Ai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance
- (2012) Bao Hoang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- TBC1D7 Is a Third Subunit of the TSC1-TSC2 Complex Upstream of mTORC1
- (2012) Christian C. Dibble et al. MOLECULAR CELL
- Tissue transglutaminase: a new target to reverse cancer drug resistance
- (2011) Alfredo Budillon et al. AMINO ACIDS
- Impaired autophagy due to constitutive mTOR activation sensitizes TSC2-null cells to cell death under stress
- (2011) Shukie Ng et al. Autophagy
- Overexpression of phospho mutant forms of transglutaminase 2 downregulates epidermal growth factor receptor
- (2011) Yi Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Targeting Ovarian Tumor Cell Adhesion Mediated by Tissue Transglutaminase
- (2011) M. Khanna et al. MOLECULAR CANCER THERAPEUTICS
- TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2
- (2011) M. Delhase et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanisms of mTOR inhibitor resistance in cancer therapy
- (2011) Jennifer S. Carew et al. Targeted Oncology
- Transglutaminase 2: a multi-functional protein in multiple subcellular compartments
- (2010) Donghyun Park et al. AMINO ACIDS
- Transglutaminase 2: A multi-tasking protein in the complex circuitry of inflammation and cancer
- (2010) Kapil Mehta et al. BIOCHEMICAL PHARMACOLOGY
- Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5
- (2010) Manuela Frese-Schaper et al. FEBS LETTERS
- Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1
- (2010) Katrin Düvel et al. MOLECULAR CELL
- Tissue Transglutaminase Promotes Drug Resistance and Invasion by Inducing Mesenchymal Transition in Mammary Epithelial Cells
- (2010) Anupam Kumar et al. PLoS One
- Molecular mechanisms of mTOR-mediated translational control
- (2009) Xiaoju Max Ma et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Common corruption of the mTOR signaling network in human tumors
- (2009) S Menon et al. ONCOGENE
- Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-κB activity in hypoxic tumor cells
- (2009) G -Y Jang et al. ONCOGENE
- Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling
- (2008) L. Cao et al. CARCINOGENESIS
- mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy
- (2008) Paolo Baldo et al. CURRENT CANCER DRUG TARGETS
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
- (2008) John J. Bissler et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now